New hope for transplant patients with life-threatening immune attack
NCT ID NCT07568535
First seen May 14, 2026 · Last updated May 15, 2026 · Updated 2 times
Summary
This study tests whether adding a special cell therapy (remestemcel-L) to standard treatment (ruxolitinib) can help adults with severe graft-versus-host disease (GVHD) that hasn't responded to steroids. GVHD is a serious complication where donor immune cells attack the patient's body after a stem cell transplant. The trial will enroll 180 participants and measure how many achieve a meaningful response by day 28.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GVHD - GRAFT-VERSUS-HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.